Diagnostic performance of 68Ga-DOTATOC PET/CT in tumor-induced osteomalacia



Tumor-induced osteomalacia (TIO) is caused by typically small tumors that secrete fibroblast growth factor 23 (FGF23). As tumor resection is the only effective treatment for TIO, it is important to detect the culprit tumor. We aimed to assess the utility of 68Gallium-DOTA-D-Phe(1)-Tyr(3)-octreotide (68Ga-DOTATOC) PET/CT in TIO and the correlation between biochemical parameters and the PET/CT results.


Thirty-five patients with clinically suspected TIO who had undergone 68Ga-DOTATOC PET/CT were retrospectively analyzed. 68Ga-DOTATOC PET/CT results were compared with biochemical parameters and the final diagnosis, including histopathology.


68Ga-DOTATOC PET/CT detected focal uptake consistent with TIO in 21/35 patients, one of which was considered false positive. In 16 patients, the cause of osteomalacia was confirmed histologically as phosphaturic mesenchymal tumor (n = 15) or fibrous dysplasia (n = 1). The other four patients were judged clinically as true positive by subsequent MRI and the clinical course. Overall, the detection rate of 68Ga-DOTATOC PET/CT was 57% (20/35). Median tumor maximum standardized uptake value (SUVmax) was 6.9 (range 1.5–37.7). There was no significant difference in serum intact FGF23 level between DOTATOC-positive and DOTATOC-negative cases, and no significant correlation was observed between intact FGF23 level and tumor SUVmax.


68Ga-DOTATOC PET/CT was clinically useful in detecting culprit tumors and subsequent patient management in TIO.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol. 2013;44:2711–8.

    CAS  Article  Google Scholar 

  2. 2.

    Reubi JC, Waser B, Laissue JA, Gebbers JO. Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: in vitro identification. Cancer Res. 1996;56:1922–31.

    CAS  PubMed  Google Scholar 

  3. 3.

    Jan-de-Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet. 2002;359:761–3.

    CAS  Article  Google Scholar 

  4. 4.

    Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med. 1999;24:130–1.

    CAS  Article  Google Scholar 

  5. 5.

    Clifton-Bligh RJ, Hofman MS, Duncan E, Sim IW, Darnell D, Clarkson A, et al. Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab. 2013;98:687–94.

    CAS  Article  Google Scholar 

  6. 6.

    Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone. 2014;64:222–7.

    CAS  Article  Google Scholar 

  7. 7.

    Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H, et al. Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients. Clin Endocrinol (Oxf). 2014;81:31–7.

    CAS  Article  Google Scholar 

  8. 8.

    Agrawal K, Bhadada S, Mittal BR, Shukla J, Sood A, Bhattacharya A, et al. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia. Clin Nucl Med. 2015;40:e6–10.

    Article  Google Scholar 

  9. 9.

    Zhang J, Zhu Z, Zhong D, Dang Y, Xing H, Du Y, et al. 68Ga DOTATATE PET/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia. Clin Nucl Med. 2015;40:642–6.

    Article  Google Scholar 

  10. 10.

    Ho CL. Ga68-DOTA peptide PET/CT to detect occult mesenchymal tumor-inducing osteomalacia: a case series of three patients. Nucl Med Mol Imaging. 2015;49:231–6.

    Article  Google Scholar 

  11. 11.

    Bhavani N, Reena Asirvatham A, Kallur K, Menon AS, Pavithran PV, Nair V, et al. Utility of Gallium-68 DOTANOC PET/CT in the localization of tumour-induced osteomalacia. Clin Endocrinol (Oxf). 2016;84:134–40.

    CAS  Article  Google Scholar 

  12. 12.

    Singh D, Chopra A, Ravina M, Kongara S, Bhatia E, Kumar N, et al. Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management. Br J Radiol. 2017;90:20160811.

    Article  Google Scholar 

  13. 13.

    El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R, et al. Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2016;101:3575–81.

    CAS  Article  Google Scholar 

  14. 14.

    Ding J, Hu G, Wang L, Li F, Huo L. Increased activity due to fractures does not significantly affect the accuracy of 68Ga-DOTATATE PET/CT in the detection of culprit tumor in the evaluation of tumor-induced osteomalacia. Clin Nucl Med. 2018;43:880–6.

    Article  Google Scholar 

  15. 15.

    Ha S, Park S, Kim H, Go H, Lee SH, Choi JY, et al. successful localization using 68Ga-DOTATOC PET/CT of a phosphaturic mesenchymal tumor causing osteomalacia in a patient with concurrent follicular lymphoma. Nucl Med Mol Imaging. 2018;52:462–7.

    Article  Google Scholar 

  16. 16.

    Maybody M, Grewal RK, Healey JH, Antonescu CR, Fanchon L, Hwang S, et al. Ga-68 DOTATOC PET/CT-guided biopsy and cryoablation with autoradiography of biopsy specimen for treatment of tumor-induced osteomalacia. Cardiovasc Intervent Radiol. 2016;39:1352–7.

    Article  Google Scholar 

  17. 17.

    Maehara J, Yamashita K, Hiwatashi A, Togao O, Kikuchi K, Matsumoto Y, et al. Primary phosphaturic mesenchymal tumour of the lumbar spine: utility of. BJR Case Rep. 2016;2:20150497.

    PubMed  PubMed Central  Google Scholar 

  18. 18.

    Kawai S, Ariyasu H, Furukawa Y, Yamamoto R, Uraki S, Takeshima K, et al. Effective localization in tumor-induced osteomalacia using 68Ga-DOTATOC-PET/CT, venous sampling and 3T-MRI. Endocrinol Diabetes Metab Case Rep. 2017;2017.

  19. 19.

    Paquet M, Gauthé M, Zhang Yin J, Nataf V, Bélissant O, Orcel P, et al. Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting ostemoalacia-associated tumours. Eur J Nucl Med Mol Imaging. 2018;45:1710–20.

    Article  Google Scholar 

  20. 20.

    Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone. 2008;42:1235–9.

    CAS  Article  Google Scholar 

  21. 21.

    Jing H, Li F, Zhuang H, Wang Z, Tian J, Xing X, et al. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan. Eur J Radiol. 2013;82:2028–34.

    Article  Google Scholar 

  22. 22.

    Johnbeck CB, Knigge U, Kjær A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10:2259–77.

    CAS  Article  Google Scholar 

  23. 23.

    Ishii A, Imanishi Y, Kobayashi K, Hashimoto J, Ueda T, Miyauchi A, et al. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels. Calcif Tissue Int. 2010;86:455–62.

    CAS  Article  Google Scholar 

  24. 24.

    Ogose A, Hotta T, Emura I, Hatano H, Inoue Y, Umezu H, et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol. 2001;30:99–103.

    CAS  Article  Google Scholar 

  25. 25.

    Uchihashi K, Nishijima-Matsunobu A, Matsuyama A, Yamasaki F, Tanabe T, Uemura T, et al. Phosphaturic mesenchymal tumor, nonphosphaturic variant, causing fatal pulmonary metastasis. Hum Pathol. 2013;44:2614–8.

    Article  Google Scholar 

  26. 26.

    Morimoto T, Takenaka S, Hashimoto N, Araki N, Myoui A, Yoshikawa H. Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases. Oncol Lett. 2014;8:67–71.

    Article  Google Scholar 

  27. 27.

    Qiu S, Cao LL, Qiu Y, Yan P, Li ZX, Du J, et al. Malignant phosphaturic mesenchymal tumor with pulmonary metastasis: a case report. Medicine (Baltimore). 2017;96:e6750.

    Article  Google Scholar 

  28. 28.

    Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1–30.

    Article  Google Scholar 

  29. 29.

    Basu S, Fargose P. 177Lu-DOTATATE PRRT in recurrent skull–base phosphaturic mesenchymal tumor causing osteomalacia: a potential application of PRRT beyond neuroendocrine tumors. J Nucl Med Technol. 2016;44:248–50.

    Article  Google Scholar 

  30. 30.

    Nair A, Chakraborty S, Dharmshaktu P, Tandon N, Gupta Y, Khadgawat R, et al. Peptide receptor radionuclide and octreotide: a novel approach for metastatic tumor-induced osteomalacia. J Endocr Soc. 2017;1:726–30.

    Article  Google Scholar 

  31. 31.

    Shaker JL, Brickner RC, Divgi AB, Raff H, Findling JW. Case report: renal phosphate wasting, syndrome of inappropriate antidiuretic hormone, and ectopic corticotropin production in small cell carcinoma. Am J Med Sci. 1995;310:38–41.

    CAS  Article  Google Scholar 

  32. 32.

    Sauder A, Wiernek S, Dai X, Pereira R, Yudd M, Patel C, et al. FGF23-associated tumor-induced osteomalacia in a patient with small cell carcinoma: a case report and regulatory mechanism study. Int J Surg Pathol. 2016;24:116–20.

    CAS  Article  Google Scholar 

  33. 33.

    Chiam P, Tan HC, Bee YM, Chandran M. Oncogenic osteomalacia – hypophosphataemic spectrum from “benignancy” to “malignancy.” Bone. 2013;53:182–7.

    CAS  Article  Google Scholar 

  34. 34.

    Mak MP, da Costa e Silva VT, Martin RM, Lerario AM, Yu L, Hoff PM, et al. Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Support Care Cancer. 2012;20:2195–7.

    Article  Google Scholar 

  35. 35.

    Leaf DE, Pereira RC, Bazari H, Jüppner H. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J Clin Endocrinol Metab. 2013;98:887–91.

    CAS  Article  Google Scholar 

  36. 36.

    Abate EG, Bernet V, Cortese C, Garner HW. Tumor induced osteomalacia secondary to anaplastic thyroid carcinoma: a case report and review of the literature. Bone Rep. 2016;5:81–5.

    Article  Google Scholar 

  37. 37.

    Dent CE, Gertner JM. Hypophosphataemic osteomalacia in fibrous dysplasia. Q J Med. 1976;45:411–20.

    CAS  PubMed  Google Scholar 

  38. 38.

    Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112:683–92.

    CAS  Article  Google Scholar 

  39. 39.

    Kobayashi K, Imanishi Y, Koshiyama H, Miyauchi A, Wakasa K, Kawata T, et al. Expression of FGF23 is correlated with serum phosphate level in isolated fibrous dysplasia. Life Sci. 2006;78:2295–301.

    CAS  Article  Google Scholar 

Download references


This study was funded by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (No. 25461816). No other potential conflict of interest relevant to this article is reported.


This study was funded by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (No. 25461816).

Author information



Corresponding author

Correspondence to Yuji Nakamoto.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kato, A., Nakamoto, Y., Ishimori, T. et al. Diagnostic performance of 68Ga-DOTATOC PET/CT in tumor-induced osteomalacia. Ann Nucl Med 35, 397–405 (2021). https://doi.org/10.1007/s12149-021-01575-x

Download citation


  • Tumor-induced osteomalacia
  • 68Ga-DOTATOC
  • Positron emission tomography
  • Fibroblast growth factor 23